Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race

Blood

Volumn 124, Issue 23, 2014, Pages 3450-3458

  Edelstein, Leonard C ^a   Simon, Lukas M ^b   Lindsay, Cory R ^a   Kong, Xianguo ^a   Teruel Montoya, Raúl ^a   Tourdot, Benjamin E ^a   Chen, Edward S ^b   Ma, Lin ^a   Coughlin, Shaun ^c   Nieman, Marvin ^d   Holinstat, Michael ^a   Shaw, Chad A ^b,e   Bray, Paul F ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 BENZYL 1H INDAZOL 3 YL)BENZOIC ACID ETHYL ESTER; INOSITOL 1,4,5 TRISPHOSPHATE; MESSENGER RNA; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN RECEPTOR; VORAPAXAR; PROTEASE-ACTIVATED RECEPTOR 4;

AMINO ACID SUBSTITUTION; ARTICLE; BLACK PERSON; CAUCASIAN; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC TRANSFECTION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; NORMAL HUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; QUANTITATIVE TRAIT LOCUS; RACE DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ANCESTRY GROUP; BLOOD CLOTTING PARAMETERS; GENETICS; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; THROMBOCYTE;

AFRICAN CONTINENTAL ANCESTRY GROUP; BLOOD PLATELETS; CONTINENTAL POPULATION GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HEK293 CELLS; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, THROMBIN;

EID: 84914680239     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-572479     Document Type: Article

References (40)

1. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012; 366(4):321-329.
2. Thomas KL, Honeycutt E, Shaw LK, Peterson ED. Racial differences in long-term survival among patients with coronary artery disease. Am Heart J. 2010;160(4):744-751.
3. Eagle KA, Ginsburg GS, Musunuru K, et al. Identifying patients at high risk of a cardiovascular event in the near future: current status and future directions: report of a national heart, lung, and blood institute working group. Circulation. 2010; 121(12):1447-1454.
4. Bray PF, Mathias RA, Faraday N, et al. Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost. 2007;5(8):1617-1623.
5. Bray PF, Mathias RA, Herrera-Galeano JE, et al. Heritability of platelet reactivity in White and African American subjects at moderately high risk of coronary artery disease. Circulation. 2005;112: 443a.
6. O'Donnell CJ, Larson MG, Feng D, et al; Framingham Heart Study. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation. 2001;103(25):3051-3056.
7. Wu CC, Hwang TL, Liao CH, et al. Selective inhibition of protease-activated receptor 4- dependent platelet activation by YD-3. Thromb Haemost. 2002;87(6):1026-1033.
8. Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med. 2002;8(10):1161-1165.
9. Hollenberg MD, Saifeddine M. Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4- derived peptides. Can J Physiol Pharmacol. 2001; 79(5):439-442.
10. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800-1814.
11. Shapiro MJ, Weiss EJ, Faruqi TR, Coughlin SR. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J Biol Chem. 2000;275(33):25216-25221.
12. Holinstat M, Voss B, Bilodeau ML, McLaughlin JN, Cleator J, Hamm HE. PAR4, but not PAR1, signals human platelet aggregation via Ca21 mobilization and synergistic P2Y12 receptor activation. J Biol Chem. 2006;281(36): 26665-26674.
13. Lova P, Campus F, Lombardi R, et al. Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin. J Biol Chem. 2004;279(24): 25299-25306.
14. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem. 2001; 276(7):4692-4698.
15. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev. 2001;53(2):245-282.
16. Henriksen RA, Hanks VK. PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. Arterioscler Thromb Vasc Biol. 2002;22(5):861-866.
17. Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003;304(2):855-861.
18. Tello-Montoliu A, Tomasello SD, Ueno M, Angiolillo DJ. Antiplatelet therapy: thrombin receptor antagonists. Br J Clin Pharmacol. 2011; 72(4):658-671.
19. Young SE, Duvernay MT, Schulte ML, Lindsley CW, Hamm HE. Synthesis of indole derived protease-activated receptor 4 antagonists and characterization in human platelets. PLoS ONE. 2013;8(6):e65528.
20. Edelstein LC, Simon LM, Montoya RT, et al. Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med. 2013;19(12):1609-1616.
21. Simon LM, Edelstein LC, Nagalla S, et al. Human platelet microRNA-mRNA networks associated with age and gender revealed by integrated plateletomics. Blood. 2014;123(16): e37-e45.
22. Nagalla S, Shaw C, Kong X, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood. 2011;117(19): 5189-5197.
23. Mumaw MM, de la Fuente M, Arachiche A, Wahl JK III, Nieman MT. Preparation of monoclonal antibodies targeted to protease activated receptor 4 (PAR4). In Preparation. 2014.
24. Li JZ, Absher DM, Tang H, et al. Worldwide human relationships inferred from genome-wide patterns of variation. Science. 2008;319(5866): 1100-1104.
25. Shapiro MJ, Trejo J, Zeng D, Coughlin SR. Role of the thrombin receptor's cytoplasmic tail in intracellular trafficking. Distinct determinants for agonist-triggered versus tonic internalization and intracellular localization. J Biol Chem. 1996; 271(51):32874-32880.
26. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51(11): 3061-3064.
27. Zhang C, Srinivasan Y, Arlow DH, et al. Highresolution crystal structure of human proteaseactivated receptor 1. Nature. 2012;492(7429): 387-392.
28. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
29. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol. 2010;30(12): 2341-2349.
30. Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol. 2006;546(1-3): 142-147.
31. Johnson AD, Yanek LR, Chen MH, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet. 2010;42(7): 608-613.
32. Muehlschlegel JD, Perry TE, Liu KY, et al. Polymorphism in the protease-activated receptor-4 gene region associates with platelet activation and perioperative myocardial injury. Am J Hematol. 2012;87(2): 161-166.
33. Zhu J, Choi WS, McCoy JG, et al. Structureguided design of a high-affinity platelet integrin alphaIIbbeta3 receptor antagonist that disrupts Mg(2)(1) binding to the MIDAS. Sci Transl Med. 2012;4(125):125ra132.
34. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem. 2004;279(6):4186-4195.
35. Zhu L, Bergmeier W, Wu J, et al. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci USA. 2007; 104(5):1621-1626.
36. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA. 1998;95(12): 6642-6646.
37. Rasmussen SG, DeVree BT, Zou Y, et al. Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature. 2011;477(7366):549-555.
38. Isberg V, Vroling B, van der Kant R, Li K, Vriend G, Gloriam D. GPCRDB: an information system for G protein-coupled receptors. Nucleic Acids Res. 2014;42(Database issue): D422-D425.
39. Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY, Teng CM. The role of PAR4 in thrombin-induced thromboxane production in human platelets. Thromb Haemost. 2003;90(2): 299-308.
40. Peng CY, Pan SL, Guh JH, et al. The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury. Thromb Haemost. 2004;92(6): 1232-1239.